Cheyenne Y Y

Dec 6, 2024 | academic.oup.com | Amsterdam UMC |Erik S. G |Vrije Universiteit Amsterdam |Cheyenne Y Y

Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection.